The AACR Annual Meeting 2024 was held in San Diego, CA from April 5-10, and featured the latest advancements in cancer research, with hundreds of poster presentations, lectures, and exhibits. Scientists, healthcare professionals, and industry experts from around the world gathered to share innovations and trends in oncology, including:
-
Advances in Diagnostics and Therapeutics
-
New Drugs and Clinical Trials
-
Computational Technologies
-
Reagents for Research Quality
-
Large Molecules and Small Molecules
Biointron Summary Report:
1. Next Generation Antibody Drug Conjugates
-
Discussions on choosing the right target, linker, conjugation technique, and payload for ADCs.
-
Pharmacokinetic properties and the role of intratumoral distribution and development of ‘auto-tuning’ ADCs for maximum efficacy.
-
Daiichi Sankyo’s DS-3939a, a novel TA-MUC1-targeting ADC with a DNA topoisomerase I inhibitor DXd, exhibited potent antitumor activity in preclinical models.
-
ProfoundBio’s novel EGFR x cMET bispecific ADC PRO1286 demonstrated broad antitumor activity and promising tolerability in preclinical models.
2. Computational Tools for Spatial Biology
-
Forecasting immunotherapy biomarkers with spatial multi-omics, a promising approach to comprehensively analyze cells in tissues.
-
MOSAIC, the world’s largest spatial multiomics dataset in oncology by Owkin, Erlangan University, CHUV, Gustave Roussy, Charité, and University of Pittsburgh.
-
Mushroom: A tool for identification of 3D cellular neighborhoods in multi-modal spatial datasets from Washington University researchers.
3. Antibody Reagents
-
University of Toronto’s A. Edwards described finding the right antibody and chemical inhibitors for cell biology applications.
-
Recombinant antibody approaches for dependable performance and reproducibility and validation at every step.
-
Research Resource Identifiers (RRIDs) are a tool to help resolve finding and identifying key resources in published literature for reproducibility.
4. Advances in Diagnostics
-
Advances in T-cell bispecific antibody targeting of solid tumors, such as DLL3 T cell engagers for SCLC and tumor-targeted co-stimulation via CD28 bispecific antibodies.
-
Using small molecules and immuno-oncology to expand covalent chemistry for targeting K-Ras (G12D), as well as the discovery of RMC-6236, a tri-complex RAS (ON)multi-selective inhibitor.
5. Novel Immunotherapies
-
Linvoseltamab, a B-cell maturation antigen-targeted T-cell-engaging bispecific antibody, induces deep and durable responses in patients with relapsed or refractory multiple myeloma, researched by Tisch Cancer Institute.
-
Agenus’ BMS-986442 (AGEN1777), a novel TIGIT/CD96 bispecific antibody, demonstrates superior monotherapy and combination activity vs. conventional anti-TIGIT antibodies.
-
BND-35, a novel anti-ILT3 antibody for remodulation of the tumor microenvironment, was presented by Biond Biologics.
6. Epigenetics in Cancer
-
Epigenetic modifiers shape immune responses against cancer by regulation of transposable elements to activate anti-tumor immunity.
-
The mechanisms of chromatin remodeling complexes in cancer (which links the genome with its functional phenotype).
-
Unknown role of HMGA1 as an epigenetic gatekeeper of Wnt signals during colon tumorigenesis and regeneration was discovered.
Thank you to everyone who visited our booth at AACR 2024 to learn about our services! We had a fantastic time chatting with you and how it can help you achieve antibody development. Our expert team would be happy to answer any follow-up questions. Feel free to email us at info@biointron.com or visit our website at www.biointron.com.
